ClearPoint Neuro, Inc. (CLPT)
After hours:
| Previous close | 5.52 |
| Open | 5.61 |
| Bid | 5.83 x 100 |
| Ask | 5.88 x 100 |
| Day's range | 5.61 - 5.87 |
| 52-week range | 4.05 - 9.87 |
| Volume | |
| Avg. volume | 156,917 |
| Market cap | 158.899M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.90 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
GlobeNewswireClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting to be held in Baltimore, MD from May 7-11. The following original research abstracts will be presented at the Poster Session: De-Risking Clinical Trials Le
GlobeNewswireClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
Key Accessory to the ClearPoint Prism® Neuro Laser Therapy Will Enable Operating Room Placement of Laser Fibers The ClearPoint Prism® Neuro Laser Therapy System The ClearPoint Prism® Neuro Laser Therapy System SOLANA BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its Prism Bone A
GlobeNewswireClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
More than Ten Operating Room Procedures Complete with Multiple Sites Reordering and Scheduling Cases SmartFrame OR logo SmartFrame OR SOLANA BEACH, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has initiated the Limited Market Release for its SmartFrame OR™ Stereotactic System. “Expanding ClearPoint’s portfolio beyond
